AML treatment

Question 1

Standard induction regimens

Answer 1

Cytarabine 100-200 mg/m2 for 7 days + daunorubicin 60-90mg/m2 or idarubicin 12mg/m2 for 3 days

Question 2

FLT3-ITD mutated AML induction regimen

Answer 2

Add midostaurin to standard induction chemo

Question 3

CD33+ AML induction

Answer 3

Add gemtuzumab ozogamicin to cytarabine + daunorubicin

Benefit seems to be in patients with favorable or intermediate risk disease

Question 4

CPX-351 indication

Answer 4

Induction for AML from prior MDS, AML with MDS-related changes, or therapy-related AML

Question 5

Consolidation therapy for favorable risk

Answer 5

HiDAC (cytarabine 3g/m2 every 12 hours on days 1, 3, and 5)

Repeat for 3-4 cycles

Question 6

Consolidation therapy for intermediate/poor risk

Answer 6

Allo transplant

Question 7

Initial therapy for older/unfit patients (multiple options)

Answer 7

Azacitadine or decitabine +/- venetoclax
Glasdegib + low dose cytarabine
Ivosidenib for IDH-1 mutated AML